{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:34:32Z","timestamp":1792218872563,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12325-024-03078-3","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T21:17:51Z","timestamp":1740691071000},"page":"1834-1859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn\u2019s Disease: Results from the Japanese CONFIDE Study"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-1204","authenticated-orcid":false,"given":"Toshifumi","family":"Hibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-4234","authenticated-orcid":false,"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7302-8692","authenticated-orcid":false,"given":"Masaru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-2469","authenticated-orcid":false,"given":"Satoshi","family":"Osaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8373-6299","authenticated-orcid":false,"given":"Alison J.","family":"Potts Bleakman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-9175","authenticated-orcid":false,"given":"Theresa","family":"Hunter Gibble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2172-8598","authenticated-orcid":false,"given":"Marijana","family":"Nedeljkovic Protic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1549-680X","authenticated-orcid":false,"given":"Isabel","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4862-8927","authenticated-orcid":false,"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"3","key":"3078_CR1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384\u2013413.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"3078_CR2","first-page":"661","volume":"98","author":"B Veauthier","year":"2018","unstructured":"Veauthier B, Hornecker JR. Crohn\u2019s disease: diagnosis and management. Am Fam Physician. 2018;98(11):661\u20139.","journal-title":"Am Fam Physician"},{"issue":"1","key":"3078_CR3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, et al. Crohn\u2019s disease. Nat Rev Dis Primers. 2020;6(1):22.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"3078_CR4","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s00535-019-01603-8","volume":"54","author":"Y Murakami","year":"2019","unstructured":"Murakami Y, Nishiwaki Y, Oba MS, et al. Estimated prevalence of ulcerative colitis and Crohn\u2019s disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol. 2019;54(12):1070\u20137.","journal-title":"J Gastroenterol"},{"issue":"11","key":"3078_CR5","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.14309\/ajg.0000000000002404","volume":"118","author":"M Dubinsky","year":"2023","unstructured":"Dubinsky M, Bleakman AP, Panaccione R, et al. Bowel urgency in ulcerative colitis: current perspectives and future directions. Am J Gastroenterol. 2023;118(11):1940\u201353.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"3078_CR6","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1007\/s11136-023-03494-y","volume":"32","author":"MC Dubinsky","year":"2023","unstructured":"Dubinsky MC, Delbecque L, Hunter T, et al. Validation of the bowel urgency numeric rating scale in patients with Crohn\u2019s disease: results from a mixed methods study. Qual Life Res. 2023;32(12):3403\u201315.","journal-title":"Qual Life Res"},{"issue":"4","key":"3078_CR7","doi-asserted-by":"crossref","first-page":"otad069","DOI":"10.1093\/crocol\/otad069","volume":"5","author":"T Matsumoto","year":"2023","unstructured":"Matsumoto T, Imai K, Goda Y, et al. Questionnaire survey for inflammatory bowel disease patients in Japan; a web-based Japan, Crohn\u2019s disease, ulcerative colitis, patients survey. Crohns Colitis 360. 2023;5(4):otad069.","journal-title":"Crohns Colitis 360"},{"issue":"1","key":"3078_CR8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000505092","volume":"5","author":"T Hibi","year":"2020","unstructured":"Hibi T, Ishibashi T, Ikenoue Y, Yoshihara R, Nihei A, Kobayashi T. Ulcerative colitis: disease burden, impact on daily life, and reluctance to consult medical professionals: results from a Japanese internet survey. Inflamm Intest Dis. 2020;5(1):27\u201335.","journal-title":"Inflamm Intest Dis"},{"issue":"5","key":"3078_CR9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00535-016-1241-x","volume":"52","author":"F Ueno","year":"2017","unstructured":"Ueno F, Nakayama Y, Hagiwara E, Kurimoto S, Hibi T. Impact of inflammatory bowel disease on Japanese patients\u2019 quality of life: results of a patient questionnaire survey. J Gastroenterol. 2017;52(5):555\u201367.","journal-title":"J Gastroenterol"},{"issue":"1","key":"3078_CR10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12325-023-02726-4","volume":"41","author":"C Wang","year":"2024","unstructured":"Wang C, Ishizuka T, Tanaka M, et al. Bowel urgency in patients with ulcerative colitis and Crohn\u2019s disease: a cross-sectional real-world survey in Japan. Adv Ther. 2024;41(1):431\u201350.","journal-title":"Adv Ther"},{"issue":"6","key":"3078_CR11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56(6):489\u2013526.","journal-title":"J Gastroenterol"},{"issue":"4","key":"3078_CR12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ibd.20793","volume":"15","author":"DT Rubin","year":"2009","unstructured":"Rubin DT, Siegel CA, Kane SV, et al. Impact of ulcerative colitis from patients\u2019 and physicians\u2019 perspectives: results from the UC: NORMAL survey. Inflamm Bowel Dis. 2009;15(4):581\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"3078_CR13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-230X-12-108","volume":"12","author":"S Schreiber","year":"2012","unstructured":"Schreiber S, Pan\u00e9s J, Louis E, Holley D, Buch M, Paridaens K. Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterol. 2012;12:108.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"3078_CR14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/MIB.0000000000001048","volume":"23","author":"DT Rubin","year":"2017","unstructured":"Rubin DT, Dubinsky MC, Martino S, Hewett KA, Pan\u00e9s J. Communication between physicians and patients with ulcerative colitis: reflections and insights from a qualitative study of in-office patient-physician visits. Inflamm Bowel Dis. 2017;23(4):494\u2013501.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"3078_CR15","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/ibd\/izab006","volume":"27","author":"DT Rubin","year":"2021","unstructured":"Rubin DT, Sninsky C, Siegmund B, et al. International perspectives on management of inflammatory bowel disease: opinion differences and similarities between patients and physicians from the IBD GAPPS Survey. Inflamm Bowel Dis. 2021;27(12):1942\u201353.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"3078_CR16","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ibd\/izad142","volume":"30","author":"S Travis","year":"2024","unstructured":"Travis S, Potts Bleakman A, Dubinsky MC, et al. The Communicating Needs and Features of IBD Experiences (CONFIDE) study: US and European patient and health care professional perceptions of the experience and impact of symptoms of moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2024;30(6):939\u201349.","journal-title":"Inflamm Bowel Dis"},{"key":"3078_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08434-5","author":"S Schreiber","year":"2024","unstructured":"Schreiber S, Hunter Gibble T, Panaccione R, et al. Patient and health care professional perceptions of the experience and impact of symptoms of moderate-to-severe Crohn\u2019 disease in US and Europe: results from the cross-sectional CONFIDE study. Dig Dis Sci. 2024. https:\/\/doi.org\/10.1007\/s10620-024-08434-5.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"3078_CR18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s41687-022-00439-w","volume":"6","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Irving PM, Panaccione R, et al. Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. J Patient Rep Outcomes. 2022;6(1):31.","journal-title":"J Patient Rep Outcomes"},{"issue":"7","key":"3078_CR19","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/ajg.2009.197","volume":"104","author":"I Clara","year":"2009","unstructured":"Clara I, Lix LM, Walker JR, et al. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol. 2009;104(7):1754\u201363.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"3078_CR20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13075-017-1421-y","volume":"19","author":"A van der Zee-Neuen","year":"2017","unstructured":"van der Zee-Neuen A, Putrik P, Ramiro S, et al. Large country differences in work outcomes in patients with RA\u2014an analysis in the multinational study COMORA. Arthritis Res Ther. 2017;19(1):216.","journal-title":"Arthritis Res Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03078-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03078-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03078-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T03:08:55Z","timestamp":1742699335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03078-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3078"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03078-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"21 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Toshifumi Hibi received consultancy fees\/grants\/research support and\/or was a speaker for AbbVie GK, ActivAid, Alfresa Pharma Corporation, Bristol Myers Squibb, Celltrion, EA Pharma, Eli Lilly and Company, Ferring Pharmaceuticals, Gilead Sciences, Janssen, JIMRO, JMDC Inc., Kyorin, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical, Nippon Kayaku Co., Pfizer, Sandoz, Takeda Pharmaceutical, Zeria Pharmaceutical, and MIYARISAN Pharmaceutical. Taku Kobayashi served as an advisory board member, consultant or speaker for AbbVie, Activaid, Alfresa Pharma, Alimentiv, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eli Lilly and Company, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Janssen Pharmaceuticals, JIMRO, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda, and Zeria Pharmaceutical, and has received research funding from AbbVie, Alfresa Pharma, EA Pharma, Gilead Sciences, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Pfizer, Sekisui Medical, Takeda, and Zeria Pharmaceutical. Masaru Tanaka and Satoshi Osaga are full time employees of Eli Lilly Japan K.K. and minor stockholders of Eli Lilly and Company. Koji Matsuo was a full-time employee of Eli Lilly Japan K.K at the time this work was completed and is now affiliated with Naramachi Internal Medicine Airi Ladies\u2019 Clinic. Alison Potts Bleakman, Theresa Hunter Gibble, Marijana Nedeljkovic Protic, and Isabel Redondo are full time employees of Eli Lilly and Company. Alison Potts Bleakman is a stockholder of Eli Lilly and Company. Tadakazu Hisamatsu received grants from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co. Ltd., AbbVie GK, JIMRO Co. Ltd., Zeria Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Mochida Pharmaceutical Co. Ltd., Boston Scientific Corporation, and Kissei Pharmaceutical Co. Ltd; consulting fees from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co. Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Pfizer Inc., Nichi-Iko Pharmaceutical Co. Ltd., Eli Lilly and Company, Gilead Sciences, and Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, EA Pharma Co. Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., and Kissei Pharmaceutical Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Pharmacoepidemiology Practice guidelines, and all local laws and regulations. All participants provided informed consent prior to participating in the study. The protocol and data collection materials were approved by the Western Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}